New registry study tracks Real-World safety of FOP drug palovarotene

NCT ID NCT06089616

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times

Summary

This study follows up to 100 children and adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease where bone grows in places it shouldn't, causing pain and disability. Researchers will collect real-world safety data on those already taking the approved drug palovarotene and compare them to untreated participants. The goal is to better understand long-term side effects and how well the drug works in daily life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bone Research and Education Centre

    ACTIVE_NOT_RECRUITING

    Oakville, Canada

  • Edmonton Clinic Health Academy (ECHA)- University of Alberta

    RECRUITING

    Edmonton, Canada

  • The Regents of the University of California

    RECRUITING

    San Francisco, California, 94103, United States

  • The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine

    ACTIVE_NOT_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University Health Network (UHN) - Toronto General

    RECRUITING

    Toronto, Canada

Conditions

Explore the condition pages connected to this study.